Table 2 Alemtuzumab meets almost all the criteria that are expected from the ideal disease-modifying immunosuppressive/immunomodulatory drug for multiple sclerosis
From: Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
Criteria of the ideal immunosuppressive drug | YES | Partially | NO |
|---|---|---|---|
Rapid biological action | X | ||
Rapid clinical effects | X | ||
Long-lasting effects | X | ||
Low frequency of injections/administrations | X | ||
Respect the patient’s quality of life | X | ||
Acceptable costs | X | ||
No non-specific toxicity | X | ||
Low risk of opportunistic infections | X | ||
No increase risk in cancer | X | ||
No increase in antibody-mediated autoimmunity | X | ||
No increase in severe antibody-mediated autoimmunity | X | ||
No increase in mortality | X | ||
Manageable cytokine-release syndrome | X | ||
Immune system re-modelling/re-shaping | X |